Skip to search formSkip to main contentSkip to account menu

zibotentan

Known as: 3-Pyridinesulfonamide, N-(3-methoxy-5-methylpyrazinyl)-2-(4-(1,3,4-oxadiazol-2-yl)phenyl)-, N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pridine-3- sulfonamide 
An orally available selective antagonist of the endothelin-A (ET-A) receptor with potential antineoplastic activity. Zibotentan binds selectively to… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminology

Broader (1)

ZD4054

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
The Endothelin-A Receptor Antagonist Zibotentan Induces Damage to the Nasal Olfactory Epithelium Possibly Mediated in Part through Type 2 Innate Lymphoid Cells
Zibotentan, an endothelin-A receptor antagonist, has been used in the treatment of various cardiovascular disorders and neoplasia… 
2016
2016
Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis.
2015
2015
Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases.
2014
2014
Efficacy of Zibotentan in Colorectal Cancer—Response
Panagiotis Vlachostergios highlights the importance of evaluating clinically the targeted therapeutic zibotentan. Despite the… 
Review
2014
Review
2014
The efficacy and safety of zibotentan in the treatment of castration-resistant prostate cancer: a meta-analysis.
OBJECTIVE Recently, novel endothelins like zibotentan and atrasentan and other novel taxanes have been introduced to treat… 
Review
2012
Review
2012
[The treatment of castration-resistant prostate cancer].
The last several years have seen extraordinary progress in the management of patients with castration resistant prostate cancer… 
2011
2011
Detection of metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic castration-resistant prostate cancer (CRPC).
4655 Background: Many patients with biochemical relapse after definitive therapy for prostate cancer receive androgen deprivation… 
2011
2011
The disposition and metabolism of zibotentan (ZD4054): an oral-specific endothelin A receptor antagonist in mice, rats and dogs
  • J.A. Clarkson-JonesA. KenyonH. Tomkinson
  • Xenobiotica; the fate of foreign compounds in…
  • 2011
  • Corpus ID: 23398460
Zibotentan (ZD4054) is an oral-specific endothelin A receptor antagonist in development for the treatment of castration-resistant… 
2010
2010
Pharmacokinetic and tolerability profile of once-daily zibotentan (ZD4054) in Japanese and Caucasian patients with hormone-resistant prostate cancer.
OBJECTIVE To investigate potential differences in zibotentan pharmacokinetics between Japanese and Caucasian patients with… 
2010
2010
Phase I study of the specific endothelin A receptor antagonist zibotentan (ZD4054) combined with docetaxel in patients with metastatic castration-resistant prostate cancer: Assessment of efficacy…
4664 Background: The combination of docetaxel and prednisone is the current standard care for patients with advanced castration… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)